Cardiff Oncology, Inc. CRDF
We take great care to ensure that the data presented and summarized in this overview for Cardiff Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRDF
View all-
Black Rock Inc. New York, NY2.63MShares$9.73 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$8.03 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$3.43 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$3.08 Million0.0% of portfolio
-
Mai Capital Management663KShares$2.45 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny602KShares$2.23 Million0.0% of portfolio
-
Morgan Stanley New York, NY498KShares$1.84 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL338KShares$1.25 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny331KShares$1.23 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL310KShares$1.15 Million0.0% of portfolio
Latest Institutional Activity in CRDF
Top Purchases
Top Sells
About CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Transactions at CRDF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,400
+3.42%
|
$12,000
$5.0 P/Share
|
|
Dec 17
2024
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,752
+4.04%
|
$13,760
$5.42 P/Share
|
|
Dec 16
2024
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,564
+3.94%
|
$7,692
$3.83 P/Share
|
|
Dec 12
2024
|
Renee P Tannenbaum |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$30,000
$3.42 P/Share
|
|
Dec 11
2024
|
Gary W Pace |
BUY
Open market or private purchase
|
Indirect |
11,500
+1.07%
|
$23,000
$2.6 P/Share
|
|
Dec 11
2024
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
350,115
+25.04%
|
$700,230
$2.6 P/Share
|
|
Dec 19
2023
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
30,000
+4.12%
|
$30,000
$1.37 P/Share
|
|
Nov 25
2022
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+29.0%
|
$10,000
$1.43 P/Share
|
|
Sep 19
2022
|
Lale White Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+11.65%
|
$15,000
$1.64 P/Share
|
|
Sep 16
2022
|
James O Armitage Director |
BUY
Open market or private purchase
|
Indirect |
13,000
+50.0%
|
$13,000
$1.56 P/Share
|
|
Sep 16
2022
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+33.33%
|
$30,000
$1.56 P/Share
|
|
Sep 15
2022
|
Renee P Tannenbaum |
BUY
Open market or private purchase
|
Direct |
10,000
+38.24%
|
$10,000
$1.72 P/Share
|
|
Sep 15
2022
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
150,000
+18.87%
|
$150,000
$1.71 P/Share
|
|
Jul 05
2022
|
Lale White Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
28,858
+22.61%
|
$57,716
$2.6 P/Share
|
|
Sep 21
2021
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
30,000
+5.72%
|
$180,000
$6.75 P/Share
|
|
Sep 10
2021
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+29.52%
|
$180,000
$6.48 P/Share
|
|
Mar 26
2021
|
Rodney S Markin Director |
BUY
Open market or private purchase
|
Indirect |
2,900
+10.83%
|
$29,000
$10.32 P/Share
|
|
Mar 23
2021
|
Gary W Pace |
BUY
Open market or private purchase
|
Direct |
10,000
+0.72%
|
$100,000
$10.24 P/Share
|
|
Mar 23
2021
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
965
+6.25%
|
$9,650
$10.34 P/Share
|
|
Mar 23
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Open market or private purchase
|
Direct |
960
+13.69%
|
$9,600
$10.31 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 379K shares |
|---|